You need JavaScript to view this

Prostate-specific antigen superior serum marker for prostatic carcinoma

Journal Article:

Abstract

A new immunoradiometric assay based on dual monoclonal antibody reaction system (Hybritech-TANDEM/sup R/) was used to measure serum levels of prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) in 39 patients with prostatic carcinoma (CaP), in 57 with benign prostatic hyperplasia (BPH) and in 14 without prostatic disease. Serum PSA was elevated in 82% of patients with CaP while PAP was elevated in only 54%. In this and other studies, PSA is superior to conventional serum markers in sensitivity, prediction of CaP stage and in longitudinal monitoring of disease. A 16% false positive rate precludes PSA as a screening test. The assay used was found to be simple and reliable.
Publication Date:
May 01, 1987
Product Type:
Journal Article
Reference Number:
AIX-19-022749; EDB-88-061013
Resource Relation:
Journal Name: Ir. J. Med. Sci.; (Ireland); Journal Volume: 156:5
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CARCINOMAS; RADIOIMMUNOASSAY; PROSTATE; ANTIGEN-ANTIBODY REACTIONS; BLOOD CHEMISTRY; DIAGNOSTIC TECHNIQUES; IMMUNE SERUMS; IODINE 125; LABELLED COMPOUNDS; MONOCLONAL ANTIBODIES; PHOSPHATASES; QUANTITATIVE CHEMICAL ANALYSIS; ANTIBODIES; BETA DECAY RADIOISOTOPES; BODY; CHEMICAL ANALYSIS; DAYS LIVING RADIOISOTOPES; DISEASES; ELECTRON CAPTURE RADIOISOTOPES; ENZYMES; ESTERASES; GLANDS; HYDROLASES; IMMUNOASSAY; IMMUNOLOGY; INTERMEDIATE MASS NUCLEI; IODINE ISOTOPES; ISOTOPE APPLICATIONS; ISOTOPES; MALE GENITALS; NEOPLASMS; NUCLEI; ODD-EVEN NUCLEI; ORGANS; RADIOASSAY; RADIOIMMUNOLOGY; RADIOISOTOPES; TRACER TECHNIQUES; 550601* - Medicine- Unsealed Radionuclides in Diagnostics
OSTI ID:
5512552
Research Organizations:
St. Vincents Hospital, Ireland. Dept. of Urology
Country of Origin:
Ireland
Language:
English
Other Identifying Numbers:
Journal ID: CODEN: IJMSA
Submitting Site:
INIS
Size:
Pages: 138-141
Announcement Date:

Journal Article:

Citation Formats

Heaney, J A, Allen, M A, Keane, T, and Duffy, J J. Prostate-specific antigen superior serum marker for prostatic carcinoma. Ireland: N. p., 1987. Web.
Heaney, J A, Allen, M A, Keane, T, & Duffy, J J. Prostate-specific antigen superior serum marker for prostatic carcinoma. Ireland.
Heaney, J A, Allen, M A, Keane, T, and Duffy, J J. 1987. "Prostate-specific antigen superior serum marker for prostatic carcinoma." Ireland.
@misc{etde_5512552,
title = {Prostate-specific antigen superior serum marker for prostatic carcinoma}
author = {Heaney, J A, Allen, M A, Keane, T, and Duffy, J J}
abstractNote = {A new immunoradiometric assay based on dual monoclonal antibody reaction system (Hybritech-TANDEM/sup R/) was used to measure serum levels of prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) in 39 patients with prostatic carcinoma (CaP), in 57 with benign prostatic hyperplasia (BPH) and in 14 without prostatic disease. Serum PSA was elevated in 82% of patients with CaP while PAP was elevated in only 54%. In this and other studies, PSA is superior to conventional serum markers in sensitivity, prediction of CaP stage and in longitudinal monitoring of disease. A 16% false positive rate precludes PSA as a screening test. The assay used was found to be simple and reliable.}
journal = {Ir. J. Med. Sci.; (Ireland)}
volume = {156:5}
journal type = {AC}
place = {Ireland}
year = {1987}
month = {May}
}